Ryan dives into the combined effects of the Enhanced Oncology Model (EOM) and the Inflation Reduction Act (IRA) on the healthcare market. He discusses the potential unintended consequences for pharmaceutical companies.
Jennifer tackles the changing landscape of prior authorization from increased payer pressure to relieve provider and patient burden coupled with the rising payer spend on pharmaceuticals. She gives solutions for how pharmaceutical companies can handle the downstream consequences of prior authorization reform.
Molly discusses the complexity of pricing, contracting, and market share around the new adalimumab biosimilars, and the strategies payers will use to maximize the cost savings on the pharmacy benefit. She provides several suggestions for pharmaceutical companies that are entering the biosimilar space.
